Impact of donor deferrals for malaria on blood availability in the United States

Transfusion

Volumn 48, Issue 10, 2008, Pages 2222-2228

  Leiby, David A ^a,b   Nguyen, Megan L ^b   Notari, Edward P ^b  

^a American Red Cross ^*  (United States)

^b Transmissible Diseases Department   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD DONOR; CALCULATION; DATA BASE; EVALUATION; HUMAN; INFECTION RISK; INFORMATION PROCESSING; MALARIA; PLASMODIUM; QUESTIONNAIRE; RED CROSS; RISK FACTOR; SAFETY; STATISTICAL ANALYSIS; TRAVEL; UNITED STATES;

BLOOD DONORS; DATABASES, FACTUAL; ENDEMIC DISEASES; HUMANS; MALARIA; RED CROSS; RISK FACTORS; TRAVEL; UNITED STATES;

EID: 52949137829     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.01825.x     Document Type: Article

References (29)

1. FDA. Interim recommendations for deferral of donors at increased risk for HIV-1 group O infection [monograph on the Internet Rockville (MD) : U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (CBER) 1996 Dec [cited 2008 Feb 19]. Available from: http://www.fda.gov/cber/bldmem/mem121196a.pdf.
2. FDA. Guidance for industry: revised preventive measures to reduce the possible risk of transmission of Creutzfeldt-Jakob Disease (CJD) and variant Creutzfeldt-Jakob Disease (vCJD) by blood and blood products [monograph on the Internet]. Rockville (MD) : U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (CBER) 2002 Apr [cited 2008 Feb 13]. Available from: http://www.fda.gov/cber/gdlns/ cjdvcjd.htm.
3. Murphy EL, Conner JD, McEvoy P, Hirschler N, Busch MP, Roberts P, Nguyen KA, Reich P. Estimating blood donor loss due to the variant CJD travel deferral. Transfusion 2004 44 : 645 50.
4. O'Brien SF, Chiavetta JA, Goldman M, Fan W, Nair RC, Sher GD, Vamvakas EC. Predictive ability of sequential surveys in determining donor loss from increasingly stringent variant Creutzfeldt-Jakob disease. Transfusion 2006 46 : 461 8.
5. AABB Bullet 03-14. Deferral for risk of leishmaniasis exposure. Bethesda : American Association of Blood Banks 2003.
6. Cox-Singh J, Davis TM, Lee KS, Shamsul SS, Matusop A, Ratnam S, Rahman HA, Conway DJ, Singh B. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis 2008 46 : 165 71.
7. Korenromp EL for the Roll Back Malaria Monitoring and Evaluation Reference Group & MERG Task Force on Malaria Morbidity. Malaria incidence estimates at country level for the year 2004 - proposed estimates and draft report [monograph on the Internet]. Geneva : Roll Back Malaria, World Health Organization 2004 cited 2007 May 3]. Available from: http://www.who.int/malaria/ docs/incidence_estimations2.pdf
8. Thwing J, Skarbinski J, Newman RD, Barber AM, Mali S, Roberts JM, Slutsker L, Arguin PM. Malaria surveillance - United States, 2005. MMWR Surveil Summ 2007 56 (SS06 23 38.
9. Centers for Disease Control and Prevention (CDC). Local transmission of Plasmodium vivax malaria - Virginia, 2002. MMWR Morb Mortal Wkly Rep 2002 51 : 921 3.
10. Centers for Disease Control and Prevention (CDC). Multifocal autochthonous transmission of malaria - Florida, 2003. MMWR Morb Mortal Wkly Rep 2004 53 : 412 3.
11. Seed CR, Cheng A, Davis TM, Bolton WV, Keller AJ, Kitchen A, Cobain TJ. The efficacy of a malarial antibody enzyme immunoassay for establishing the reinstatement status of blood donors potentially exposed to malaria. Vox Sang 2005 88 : 98 106.
12. Kitchen AD, Chiodini PL. Malaria and blood transfusion. Vox Sang 2006 90 : 77 84.
13. Leiby DA. Making sense of malaria. Transfusion 2007 47 : 1573 7.
14. FDA. Draft guidance for industry: recommendations fordonor questioning regarding possible exposure to malaria [monograph on the Internet]. Rockville (MD) : U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (CBER) 2000 Jun [cited 2007 Oct 16]. Available from: http://www.fda.gov/cber/gdlns/malaria.htm.
15. Zou S, Eder AF, Musavi F, Notari EP, Fang CT, Dodd RY. Implementation of the Uniform Donor History Questionnaire across the American Red Cross Blood Services: increased deferral among repeat presenters but no measurable impact on blood safety. Transfusion 2007 47 : 1990 8.
16. Zou S, Musavi F, Notari EP, Fujii KE, Dodd RY. Prevalence of selected viral infections among temporarily deferred donors who returned to donate blood: American Red Cross blood donor study. Transfusion 2005 45 : 1593 600.
17. Custer B, Chinn A, Hirschler NV, Busch MP, Murphy EL. The consequences of temporary deferral on future whole blood donation. Transfusion 2007 47 : 1514 23.
18. Katz LM, Kabat A. Return behavior of blood donors after expiration of a 1-year malarial travel deferral. Transfusion 2007 47 : 356 7.
19. Spencer BR, Custer B, Kakaiya RM, Hillyer KL, Wilkinson SL, Gottschall JL, Steele WR. Low risk for malaria transmission from presenting blood donors excluded for travel to Mexico [abstract Transfusion 2006 46 Suppl : 27A.
20. Mungai M, Tegtmeier G, Chamberland M, Parise M. Transfusion-transmitted malaria in the United States from 1963 through 1999. N Engl J Med 2001 344 : 1973 8.
21. Arafat R, Long S, Perry M, Marsh S, Wilson M, Avashia S, Filler S. Probable transfusion-transmitted malaria - Houston, Texas, 2003. MMWR Mortal Wkly Rep 2003 52 : 1075 6.
22. Purdy E, Perry E, Gorlin J, Jensen K. Transfusion-transmitted malaria: unpreventable by current donor exclusion guidelines? Transfusion 2004 44 : 464.
23. Parise ME. Traveler's malaria, locally-transmitted malaria, and transfusion-transmitted malaria in the United States [monograph on the Internet]. FDA Workshop on Testing for Malarial Infections in Blood Donors. Atlanta (GA) : Centers for Disease Control and Prevention 2006 Jul 12 [cited 2007 Oct 16]. Available from: http://www.fda.gov/cber/blood/malaria071206mp.pdf.
24. Bruneel F, Thellier M, Eloy O, Mazier D, Boulard G, Danis M, Bédos JP. Transfusion-transmitted malaria. Intensive Care Med 2004 30 : 1851 2.
25. Reesink HW, Engelfriet CP. International forum. Are current measures to prevent transfusion-associated protozoal infections sufficient? Vox Sang 2004 87 : 125 38.
26. Slinger R, Giulivi A, Bodie-Collings M, Hindieh F, St. John R, Sher G, Goldman M, Rickets M, Kain KC. Transfusion-transmitted malaria in Canada. CMAJ 2001 164 : 377 9.
27. Kitchen AD, Lowe PH, Lalloo K, Chiodini PL. Evaluation of a malarial antibody assay for use in the screening of blood and tissue products for clinical use. Vox Sang 2004 87 : 150 5.
28. Singh Y, Sawyer LS, Pinkoski LS, Dupuis KW, Hsu JC, Lin L, Corash L. Photochemical treatment of plasma with amotosalen and long-wavelenth ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 2006 46 : 1168 77.
29. Webert KE, Cserti CM, Hannon J, Lin Y, Pavenski K, Pendergrast JM, Blajchman MA. Proceedings of a consensus conference: pathogen inactivation-making decisions about new technologies. Transfus Med Rev 2008 22 : 1 34.